Product Description
A2B694 is a autologous CAR-T cell candidate from A2 Bio, which acts as a MSLN activator and HLA-A*02 blocker for the treatment of Ovarian, Mesothelioma, Colorectal, Lung and Pancreatic Cancers. (Sourced from: https://www.a2bio.com/our-pipeline/)
Mechanisms of Action: Cell Therapy, HLA
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: A2 Bio
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Colorectal Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06051695 |
EVEREST-2 | P2 |
Recruiting |
Pancreatic Cancer|Colorectal Cancer|Ovarian Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Adenocarcinoma|Mesothelioma |
2028-06-01 |
12% |
2025-12-13 |
Primary Endpoints |